Vedolizumab is used to treat patients with ulcerative colitis (UC), although there is a delay before it is effective. Induction therapy with a calcineurin inhibitor (cyclosporine or tacrolimus) in combination with vedolizumab as maintenance therapy could be an option for patients with an active steroid-refractory UC. We assessed the efficacy and safety of this combination.
BACKGROUND & AIMS:
Vedolizumab is used to treat patients with ulcerative colitis (UC), although there is a delay before it is effective. Induction therapy with a calcineurin inhibitor (cyclosporine or tacrolimus) in combination with vedolizumab as maintenance therapy could be an option for patients with an active steroid-refractory UC. We assessed the efficacy and safety of this combination.
METHODS:
We performed a retrospective observational study, collecting data from 12 referral centers in France that were included in the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif. We collected information on 39 patients with an active steroid-refractory UC (31 with active severe UC and 36 failed by treatment with a tumor necrosis factor antagonist) who received a calcineurin inhibitor as induction therapy along with vedolizumab as maintenance therapy. Inclusion date was the first vedolizumab infusion. The outcomes were survival without colectomy, survival without vedolizumab discontinuation, and safety.
See related article on page 486.
U lcerative colitis (UC) is a chronic inflammatory bowel disease that always affects the rectum with a retrograde continuous extent into the colon. The 2 main criteria 1 driving UC treatment are disease extent and severity. Indeed, treatment is based mainly on topical therapy when UC is limited to the rectum, whereas systemic treatments are needed in more extensive disease. 2 Approximately 20% of UC patients will experience an acute severe flare during their life. In patients with uncomplicated acute severe UC (ASUC), a standardized rapid step-up medical approach is needed. 2 It is recommended to start with intravenous steroids and to give cyclosporine or infliximab as a second-line medical therapy in steroid-refractory patients. 3, 4 Regarding cyclosporine and because of its long-term toxicity, it is given as a bridging therapy to thiopurine in patients without prior failure to these agents.
During the past decades, thiopurines, cyclosporine, and infliximab increasingly have been prescribed in patients admitted to tertiary centers for active UC. 5 Accordingly, there has been a trend toward a decrease in colectomy rates. 6 As a consequence, there is an increasing number of ASUC patients losing response, especially to anti-tumor necrosis factor (TNF), who now are admitted to referral centers.
Vedolizumab has shown its efficacy in UC, as an induction and maintenance therapy, in patients who have been exposed or not to thiopurines and anti-TNF. 7, 8 However, it acts progressively and can takes 14 weeks to reach its full efficacy. 9 Vedolizumab has never been evaluated in the setting of ASUC where a prompt efficacy is required. Therefore, a strategy combining a calcineurin inhibitor (cyclosporine or tacrolimus) as an induction therapy with vedolizumab as maintenance could be an attractive approach for UC patients who have failed treatment with thiopurines and anti-TNF or who have a contraindication to these drugs. The aim of the present study was to assess the efficacy and safety of this combination in patients with steroid-and anti-TNF-refractory UC.
Methods

Study Design and Patients
We performed a retrospective multicenter observational study in 12 French tertiary academic centers affiliated with the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif.
From December 2014 to May 2017, patients with an active steroid-refractory UC were enrolled consecutively when they received a calcineurin inhibitor (cyclosporine or tacrolimus) as an induction therapy and vedolizumab as maintenance. Patients were eligible when they were admitted for a refractory UC that could be an ASUC (defined according to the Truelove and Witts 10 criteria) or not, and if they previously did not respond adequately to at least 1 anti-TNF agent or if it was contraindicated. Baseline corresponded to the date of the first vedolizumab infusion.
Cyclosporine was started by continuous intravenous infusion at an initial dose of 2 mg/kg/d or orally at 4 mg/kg/d. The dose subsequently was adjusted to obtain a cyclosporine concentration between 150 and 250 ng/ mL. When response was achieved with intravenous cyclosporine, it was switched to an oral drug (Neoral; Novartis Pharmaceuticals, Frimley, UK) given twice a day at 4 mg/kg/d. Tacrolimus was started orally at 0.05 to 0.1 mg/kg/d secondarily adjusted to plasmatic concentration, targeting a blood concentration of 10-15 ng/ mL until week 2 and 5-10 ng/mL thereafter. The choice of calcineurin inhibitor molecule, cyclosporine or tacrolimus, depended on the routine practice of the center. Both calcineurin inhibitors were given as a bridge therapy to vedolizumab for approximately 3 months in responders. They were withdrawn intentionally at this time, or previously in case of intolerance or failure.
In France, vedolizumab is licensed only in patients who have failed treatment with anti-TNF or in whom these drugs are contraindicated. Inclusion date was the first vedolizumab infusion.
All patients received treatment according to clinical need. Medications were those currently recommended in UC according to their licensed or published doses. Patients were informed by written notice of their participation. The French Data Protection Agency (Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé, approval 17-037) and investigational review board of each center approved the study.
All authors had access to the study data and reviewed and approved the final manuscript.
What You Need to Know Background
We performed a retrospective study of the effects of induction therapy with a calcineurin inhibitor (cyclosporine or tacrolimus) in combination with vedolizumab in 39 patients with active refractory ulcerative colitis (most of whom were failed by tumor necrosis factor antagonists).
Findings
Sixty-eight percent of patients who received this treatment combination were colectomy-free 1 year after initiation of the therapy, without a safety signal.
Implications for patient care
This approach can be considered in patients with severe or nonsevere refractory ulcerative colitis who are refractory to all conventional therapies.
Data Collection
At inclusion, the following characteristics were recorded for each patient: sex, age, disease duration, smoking status, UC characteristics according to the Montreal Classification, extraintestinal manifestation, prior received treatments (steroids, thiopurine, methotrexate, infliximab, adalimumab, and golimumab) and reasons for discontinuation (primary failure, loss of response, or intolerance), disease activity according to the partial Mayo score and the Lichtiger score, endoscopic activity measured with the endoscopic Mayo subscore and UC endoscopic index of severity, severe endoscopic lesions, C-reactive protein (CRP), hemoglobin, and albumin levels.
Follow-up Evaluation
The follow-up period started at inclusion and lasted up until August 2017.
Infusions of 300 mg vedolizumab were administered intravenously at weeks 0, 2, and 6, and then every 8 weeks. If needed, vedolizumab could be prescribed every 4 weeks from week 10. Other UC treatments, including calcineurin inhibitors, corticosteroids, or thiopurines, were given according to clinical need as judged by the physician. The treatment duration of each drug was collected during the follow-up period.
UC clinical activity (according to the partial Mayo score), treatments received, and CRP measurements were collected at each vedolizumab infusion (ie, at least at weeks 2, 6, and 14) until death, colectomy, vedolizumab discontinuation, or end of the follow-up period. Reasons for vedolizumab withdrawal were collected and investigated. Because of its retrospective design, no standardized endoscopic assessment was performed during the study.
Each adverse event occurring during the follow-up period was collected and investigated.
Objectives
The primary objective was survival without colectomy. Secondary objectives were survival without colectomy according to disease severity, survival without vedolizumab discontinuation, clinical response at weeks 6 and 14, clinical remission at weeks 6 and 14, biochemical remission at weeks 6 and 14, and predictive factors of colectomy and safety.
Clinical response was defined by a decrease of the partial Mayo score of at least 3 points, with a decrease of at least 30% and a reduction of at least 1 point on the bleeding subscore with a subscore of 0 or 1, as compared with inclusion. Clinical remission was defined by a partial Mayo score of less than 3, without any of the subscores having a value higher than 1. Biochemical remission was defined by a normal CRP level (eg, <5 mg/L). Adverse effects were classified as severe when they lead to treatment interruption, hospitalization, or death.
Statistical Analysis
Continuous variables were reported as medians and ranges. They were compared with the Student t test or Mann-Whitney-Wilcoxon test for variables with abnormal distribution, and categoric variables with the Pearson chisquare or the Fisher exact tests where appropriate. Regarding assessments at weeks 6 and 14, patients who underwent colectomy or vedolizumab discontinuation since inclusion were considered as treatment failures.
For the survival analysis, a Kaplan-Meier curve and a log-rank test were used. Because there were no deaths in our study population, there was no need for considering competitive risk. Cox proportional hazard models were used to identify predictors of surgery. Variables associated with colectomy with a P value less than .30 in univariate analysis were included in the multivariate model. ASUC is a well-known risk factor for colectomy and was forced into the multivariate model, whatever the result of the univariate analysis. The final Cox model was obtained by a backward stepwise selection of variables with a P value less than .05. SAS software 9.4 and R were used for statistical analysis.
Results
Patient Characteristics
Thirty-nine UC patients were included in 12 centers during the study period. Their main characteristics are shown in Table 1 . To summarize, 23 patients (59%) were women, with a median age of 32 years (range, 17-73 y). None underwent prior liver transplantation. The median disease duration was 4.0 years (range, 0.2-23.9 y) and 31 patients (79%) were admitted for an ASUC. Thirty-three patients (85%) had been exposed to thiopurines previously, 1 patient (%) to methotrexate, and 36 patients (92%) to at least 1 anti-TNF agent. Three (8%) other patients had a contraindication to anti-TNF agents because of multiple sclerosis (1 patient), recent malignancy (1 patient), or tuberculosis (1 patient). Twenty-six (67%) patients received an anti-TNF agent in the 3 previous months, and 13 (33%) in the past month. The median interval between the last anti-TNF administration and first vedolizumab infusion was 43 days (range, 7-3230 d). Thirty (77%) patients received corticosteroids at baseline. Regarding calcineurin inhibitors, 37 (95%) patients received cyclosporine and 2 (5%) received tacrolimus. Vedolizumab was started after a median interval of 7 days (range, 0-180 d) after the calcineurin inhibitor (1 patient received cyclosporine for 180 days while waiting for vedolizumab approval in France). Thirty-six (92%) patients started calcineurin inhibitors before vedolizumab. The remaining 3 patients started a calcineurin inhibitor during the vedolizumab induction regimen, within a median interval of 30 days. The calcineurin inhibitor was continued for a median duration of 80 days (range, 5-384 d) since inclusion.
Efficacy
The median duration of follow-up evaluation was 10.8 months (range, 0.4-30.2 mo). No deaths occurred and no patient was lost to follow-up evaluation.
Eleven (28%) patients underwent colectomy after a median duration of 112 days (range, 11-344 d). Six of these patients underwent early surgery before week 14.
The survival rate without colectomy was 68% at 1 year (95% CI, 53%-84%) ( Figure 1A) .
At 1 year, rates of survival without colectomy were 64% (95% CI, 46%-83%) in patients with ASUC and 87% (95% CI, 65%-100%) in patients without ASUC (P ¼ .32) ( Figure 1B ).
Nineteen (49%) patients stopped vedolizumab during the study period: 18 because of a lack of efficacy and 1 because of intolerance (depression). After 1 year of follow-up evaluation, 44% (IC95%, 27%-61%) of patients still were treated with vedolizumab ( Figure 2) . Vedolizumab was intensified every 4 weeks in 26 patients (67%; in 19 patients at week 10 and in 7 patients after week 14). Among the 19 optimized patients at week 10, 9 (47%) were in clinical remission at week 14. Regarding the 18 patients who did not respond to vedolizumab, 11 underwent colectomy and 7 were treated with another medical treatment (combination therapy with infliximab and thiopurines for 2 patients; inclusion in a clinical trial for 3 patients, tofacitinib in 2 patients and fecal microbiota transplantation in 1 patient; allopurinol plus thiopurine for 1 patient; and oral tacrolimus for 1 patient).
The median partial Mayo scores were 7 at baseline, 2 at week 6, and 3 at week 14. Clinical response and clinical remission were achieved in 25 of 39 patients (64%) and in 18 of 39 patients (46%) at week 6, and in 22 of 39 patients (56%) and 15 of 39 patients (38%) at week 14, respectively (Figure 3) . Among the 30 patients receiving corticosteroids at baseline, steroid-free remission was achieved in 7 of 30 patients (23%) at week 6, and in 12 of 30 patients (40%) at week 14. Proportions of patients still receiving the calcineurin inhibitor were 25 of 39 patients (64%) at week 6, and 8 of 39 patients (21%) at week 14.
There were 9 of 32 patients (28%) in biochemical remission (CRP, <5 mg/L) at week 6 and 8 of 34 patients (24%) at week 14. The median CRP level was 6 mg/L at week 6, and 7.8 mg/L at week 14.
In multivariate analysis, 4 baseline factors were associated with colectomy during the follow-up period: female sex (hazard ratio [HR], 10.5; 95% CI, 2.05-54.33; P ¼ .004), age older than 31 years (HR, 13.16; 95% CI, 2.27-76.26), concomitant immunosuppressant (HR, 9.59; 95% CI, 1.13-81.60), and hemoglobin level higher than 11.2 g/dL (HR, 1.93; 95% CI, 0.59-6.32).
Safety
Eleven (28%) patients experienced at least 1 adverse event during the study. They are summarized in Table 2 . Four of them were severe: 3 patients developed mild and transient renal failure, leading to cyclosporine withdrawal in 1 case and, 1 patient developed a Campylobacter jejuni colitis while treated with vedolizumab and tacrolimus, which completely recovered with antibiotics. No opportunistic infection or malignancy was observed. One patient in clinical remission decided to stop vedolizumab because of a depression that was thought to be caused by the drug.
Discussion
In the present multicenter cohort of patients admitted for steroid-refractory UC with prior anti-TNF failure, a combination of a calcineurin inhibitor with vedolizumab could avoid colectomy in approximately 2 of 3 patients within 1 year, whatever the disease severity, with a good safety profile. This was a large study that investigated this association in a cohort of highly selected patients with refractoriness to all current licensed drugs in UC. 11, 12 The number of UC anti-TNF refractory patients is de facto increasing in parallel with the growing use of these drugs. Currently, these patients are candidates for either vedolizumab or colectomy. Until now, vedolizumab has not been evaluated in patients with ASUC who were excluded from the pivotal trials. In addition, physicians are reluctant to use vedolizumab in this setting because of its delayed efficacy. 7, 9 However, and as a parallel with the bridging strategy combining cyclosporine and thiopurine in the management of patients with steroidrefractory UC before the anti-TNF era, 13 it could be attractive to combine a calcineurin inhibitor as induction therapy with vedolizumab as maintenance in these patients.
Although patients recruited in the present cohort, UC was more severe, the efficacy of vedolizumab was similar with that reported in the literature for treatment of UC. Published clinical response and remission rates at week 14 were 43% to 57% and 23% to 39%, respectively, as compared with 56% and 38%, respectively, in our cohort. In addition, reported vedolizumab failure rates within the first year of treatment were 35% to 48% in previous series, [14] [15] [16] and 49% in our cohort.
However, because vedolizumab was given as a lastchance drug before surgery in the present cohort, the absence of colectomy during the follow-up period does not necessarily mean that the drug was efficient. Indeed, half of the patients discontinued vedolizumab within 1 year, while approximately one third underwent surgery. Moreover, some patients continued the drug despite partial efficacy. This illustrates the impact of a limited therapeutic choice on drug persistence.
In ASUC patients from the present cohort, the 1-year colectomy rate of 36% was similar to those reported with cyclosporine (29%) or infliximab (31%) when combined with azathioprine after intravenous steroid failure. 17 As observed in controlled trials and observational studies, vedolizumab appears to have a good safety profile. 8 However, concomitant use of a calcineurin inhibitor was not allowed in the pivotal phase 3 trial and the experience of combining an anti-integrin with a calcineurin inhibitor is very limited in UC as well as in multiple sclerosis. A prior study conducted in 9 patients with Crohn's disease and in 11 patients with UC did not observe additional safety events other than those related to calcineurin inhibitors alone. Adverse events observed in the present cohort were mostly related to calcineurin inhibitors, except 1 case of C jejuni colitis associated with vedolizumab. No other case of opportunistic infection or malignancy was observed.
This study had several limitations inherent to its retrospective design. Treatments were not standardized as well as outcome measures, especially endoscopic assessments. Patients were selected in few referral centers and most of them were primary responders to calcineurin inhibitors who received vedolizumab only when they responded adequately to the induction therapy. The follow-up period was limited to 11 months.
Overall, a strategy combining a calcineurin inhibitor with vedolizumab in patients with steroid-refractory UC and prior anti-TNF failure or contraindication can avoid colectomy in approximately two thirds of the patients within 1 year and seems safe. It can be considered in patients with ASUC or nonsevere UC when they are refractory to all conventional therapies, including anti-TNF agents. The safety profile of this combination will require further investigation.
